<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Adult preventive services (ages 50 - 65+).&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Adult preventive services (ages 50 - 65+). Southfield (MI): Michigan Quality Improvement Consortium; 2013 Mar. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Adult preventive services (50-65+). Southfield (MI): Michigan Quality Improvement Consortium; 2011 Apr. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Acute myocardial infarction of unspecified site, episode of care unspecified  (410.90); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled  (250.01); Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled  (250.00); Diphtheria, unspecified  (032.9); General physical examination  (89.7); Herpes zoster without mention of complication  (053.9); Human immunodeficiency virus [HIV] disease  (042); Major depressive affective disorder, recurrent episode, unspecified  (296.30); Malignant neoplasm of breast (female), unspecified  (174.9); Malignant neoplasm of cervix uteri, unspecified site  (180.9); Malignant neoplasm of colon, unspecified site  (153.9); Malignant neoplasm of prostate  (185); Malignant neoplasm of rectum  (154.1); Meningococcal infection, unspecified  (036.9); Obesity, unspecified  (278.00); Osteoporosis, unspecified  (733.00); Overweight  (278.02); Pneumonia due to Streptococcus, unspecified  (481); Pneumonia due to Streptococcus, unspecified  (482.30); Tetanus  (037); Tobacco use disorder  (305.1); Unspecified disorder of lipoid metabolism  (272.9); Varicella without mention of complication  (052.9); Viral hepatitis A without mention of hepatic coma  (070.1); Viral hepatitis B without mention of hepatic coma, acute or unspecified, without mention of hepatitis delta  (070.30); Whooping cough due to bordetella pertussis [B. pertussis]  (033.0)"/><FieldValue Value="MSH: AIDS Serodiagnosis ; Alcoholism ; Aspirin ; Blood Chemical Analysis ; Blood Pressure Determination ; Body Height ; Body Weight ; Breast Neoplasms ; Chickenpox ; Chickenpox Vaccine ; Colorectal Neoplasms ; Counseling ; Depression ; Diabetes Mellitus ; Diphtheria ; Diphtheria-Tetanus Vaccine ; Diphtheria-Tetanus-acellular Pertussis Vaccines ; Domestic Violence ; Dyslipidemias ; Early Detection of Cancer ; Hepatitis A ; Hepatitis A Vaccines ; Hepatitis B ; Hepatitis B Vaccines ; Herpes Zoster ; Herpes Zoster Vaccine ; Herpesvirus Vaccines ; HIV Infections ; Hypertension ; Immunization ; Influenza Vaccines ; Influenza, Human ; Lipid Metabolism Disorders ; Mammography ; Mass Screening ; Medical History Taking ; Meningococcal Infections ; Meningococcal Vaccines ; Myocardial Infarction ; Obesity ; Osteoporosis ; Overweight ; Physical Examination ; Pneumococcal Vaccines ; Pneumonia, Pneumococcal ; Preventive Health Services ; Prostatic Neoplasms ; Risk Assessment ; Substance Abuse Detection ; Substance-Related Disorders ; Tetanus ; Tobacco Use Disorder ; Uterine Cervical Neoplasms ; Vaginal Smears ; Whooping Cough "/><FieldValue Value="MTH: Acute myocardial infarction ; AIDS Serodiagnosis measurement ; Alcoholic Intoxication, Chronic ; Aspirin ; Behavior assessment ; Blood Chemical Analysis ; Blood pressure determination ; Body Height ; Body Weight ; Chickenpox ; Chickenpox Vaccine ; Colorectal Carcinoma ; Counseling ; Diabetes Mellitus ; Diabetes Mellitus screen ; Diphtheria ; Diphtheria-Tetanus Vaccine ; Domestic Violence ; Drug abuse screening test ; Early Detection of Cancer ; Hepatitis A ; Hepatitis A Vaccines ; Hepatitis B ; Hepatitis B Vaccines ; Herpes zoster disease ; Herpes Zoster Vaccine ; Herpes zoster without mention of complication ; HIV Infections ; HIV screen ; Hypertensive disease ; Immunization ; Individual safety assessment ; Influenza ; Influenza virus vaccine ; Lipid Metabolism Disorders ; Malignant neoplasm of breast ; Malignant neoplasm of female breast ; Malignant neoplasm of prostate ; Malignant Rectal Neoplasm ; Malignant tumor of cervix ; Malignant tumor of colon ; Mammary Neoplasms ; Mammography ; Meningococcal Infections ; Meningococcal vaccine ; Mental Depression ; Myocardial Infarction ; Obesity ; Osteoporosis ; OVERWEIGHT ; Pap smear ; Pertussis ; physical examination ; Pneumococcal vaccine ; Prostatic Neoplasms ; Risk Assessment ; Screening for cancer ; Screening for osteoporosis (procedure) ; Streptococcal pneumonia ; Substance Abuse Detection ; Substance abuse problem ; Tetanus ; Tobacco Use Disorder ; Uterine Cervical Neoplasm "/><FieldValue Value="PDQ: acetylsalicyclic acid ; mammography ; obesity ; osteoporosis ; Pap test ; substance abuse disorder ; tobacco use disorder "/><FieldValue Value="SNOMEDCT_US: Acute myocardial infarction  (57054005); Alcohol consumption screening  (171208001); Alcoholism  (284591009); Alcoholism  (66590003); Alcoholism  (7200002); Aspirin  (387458008); Aspirin  (7947003); Behavior assessment  (165309004); Behavior assessment  (225385005); Behavior assessment  (396068002); Blood chemistry  (166312007); Blood pressure taking  (46973005); Body height measure  (50373000); Body weight  (27113001); Counseling  (129441002); Counseling  (409063005); Diabetes mellitus  (73211009); Diabetes mellitus screening  (171183004); Diphtheria  (276197005); Diphtheria  (397428000); Diphtheria + tetanus + acellular pertussis vaccine  (429321000124106); Diphtheria + tetanus vaccine  (350327004); Diphtheria + tetanus vaccine  (73152006); Disorder of lipid metabolism  (267431006); Domestic violence  (404189009); Drug abuse screening test  (273426006); Dyslipidemia  (370992007); Examination of breast  (46662001); Herpes zoster  (4740000); HIV screening  (171121004); Human immunodeficiency virus infection  (86406008); Hyperlipidemia screening  (268552003); Hypertensive disorder  (38341003); Immunization  (127785005); Individual safety assessment  (385876007); Influenza  (6142004); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Malignant neoplasm of female breast  (372064008); Malignant neoplasm of rectum, rectosigmoid junction and anus  (187760008); Malignant tumor of breast  (254837009); Malignant tumor of cervix  (363354003); Malignant tumor of colon  (363406005); Malignant tumor of prostate  (399068003); Malignant tumor of rectum  (363351006); Mammography  (71651007); Meningococcal infectious disease  (23511006); Meningococcus vaccine  (423531006); Meningococcus vaccine  (424891007); Myocardial infarction  (22298006); Neoplasm of breast  (126926005); Neoplasm of large intestine  (126837005); Neoplasm of prostate  (126906006); Neoplasm of uterine cervix  (123841004); Obesity  (414915002); Obesity  (414916001); Osteoporosis  (64859006); Overweight  (238131007); Pertussis  (27836007); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Pneumonia due to Streptococcus  (233607000); Pneumonia due to Streptococcus  (34020007); Recurrent major depressive episodes  (268621008); Recurrent major depressive episodes  (66344007); Risk assessment  (225338004); Screening for cancer  (15886004); Screening for osteoporosis  (300004007); Screening for substance abuse  (370854007); Screening for substance abuse  (89732002); Substance abuse  (66214007); Tetanus  (276202003); Tetanus  (76902006); Tobacco dependence syndrome  (89765005); Type B viral hepatitis  (66071002); Varicella  (38907003); Varicella virus vaccine  (108729007); Varicella virus vaccine  (396442000); Viral hepatitis A without hepatic coma  (111879004); Viral hepatitis, type A  (40468003)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Preventable diseases and conditions, including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Overweight/obesity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Alcohol and tobacco use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Myocardial infarction (MI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dyslipidemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Colorectal cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cervical cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Breast cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prostate cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tetanus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diphtheria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pertussis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Varicella infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Herpes zoster infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Influenza &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pneumococcal pneumonia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatitis A (HepA), hepatitis B (HepB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Meningococcal infection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;To achieve significant, measurable improvements in the management of adult preventive services (ages 50 to 65+) through the development and implementation of common evidence-based clinical practice guidelines&lt;/li&gt;&#xA;    &lt;li&gt;To design concise guidelines that are focused on key management components of adult preventive services (ages 50 to 65+) to improve outcomes&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients ages 50 to 65+ years&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening/Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Health maintenance exam (HME) including height, weight and body mass index (BMI); risk evaluation and counseling for obesity, tobacco use, and alcohol use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aspirin (ASA) use (for the prevention of myocardial infarction [MI]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for the following diseases/conditions:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;High blood pressure (BP) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dyslipidemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Diabetes mellitus &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Osteoporosis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Colorectal cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cervical cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Breast cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Prostate cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunizations:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Tetanus, diphtheria, and acellular pertussis/tetanus-diphtheria (Tdap/Td) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Varicella &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Zoster &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Influenza &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pneumococcal &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hepatitis A (HepA), hepatitis B (HepB) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Meningococcal &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the current update of the guideline the United States Preventive Services Task Force (USPSTF) and Advisory Committee on Immunization Practices (ACIP) databases were searched. No date restrictions were used and no specific inclusion/exclusion criteria were applied.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the Medical Directors' Committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee, resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the Medical Directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the Medical Directors' Committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Recommendation Grades*&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A.&lt;/strong&gt; The United States Preventive Services Task Force (USPSTF) recommends the service. There is high certainty that the net benefit is substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B.&lt;/strong&gt; The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C.&lt;/strong&gt; The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D.&lt;/strong&gt; The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I.&lt;/strong&gt; The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*The grade definitions used for this guideline are as defined by the USPSTF.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the Medical Directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to Medical Directors' Committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies and physicians with expertise in the related field for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC Medical Directors approved this updated guideline in March 2013.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations grades (&lt;strong&gt;A-D&lt;/strong&gt; and &lt;strong&gt;I&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Health Assessment Screening, History, and Counseling&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One health maintenance exam (HME) every 1 to 3 years according to risk status, including: Height, weight and body mass index (BMI) &lt;strong&gt;[B]&lt;/strong&gt;; risk evaluation and counseling for obesity (BMI &amp;ge;30) &lt;strong&gt;[B]&lt;/strong&gt;, tobacco use &lt;strong&gt;[A]&lt;/strong&gt;, and alcohol use &lt;strong&gt;[B]&lt;/strong&gt;. (See the National Guideline Clearinghouse [NGC] summaries of the Michigan Quality Improvement Consortium [MQIC] guidelines: &lt;a href=&quot;/content.aspx?id=46654&quot; title=&quot;Guideline #9933&quot;&gt;Management of overweight and obesity in the adult&lt;/a&gt;, &lt;a href=&quot;/content.aspx?id=47550&quot; title=&quot;Guideline #10086&quot;&gt;Tobacco control&lt;/a&gt; and &lt;a href=&quot;/content.aspx?id=47911&quot; title=&quot;Guideline #10317&quot;&gt;Screening, diagnosis and referral for substance use disorders&lt;/a&gt;.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Blood Pressure (BP) Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Screen for high BP in adults &lt;strong&gt;[A]&lt;/strong&gt;. Screen every two years if BP &amp;le;120/80 mm Hg. Annually if BP 120-139/80-89 mm Hg, and more frequently if warranted.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Aspirin (ASA) Use&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommend the use of ASA for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarction (MI) outweighs the potential harm due to an increase in gastrointestinal hemorrhage &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommend the use of ASA for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cholesterol and Lipid Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Measure a fasting lipoprotein profile (i.e., total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]) in men aged 35 years and older &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measure a fasting lipoprotein profile in women aged 45 years and older if they are at increased risk for coronary heart disease (CHD) (i.e., diabetes, family history of cardiovascular disease before age 50 in male relatives or age 60 in female relatives, tobacco use, hypertension, BMI &amp;ge;30) &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screen every five years for low risk adults if initial test normal; consider more frequent screening in individuals at increased risk. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diabetes Mellitus Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen for type 2 diabetes in asymptomatic adults with sustained BP (either treated or untreated) greater than 135/80 mm Hg &lt;strong&gt;[B]&lt;/strong&gt;. Screen every three years. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In persons with BP &amp;le;135/80 mm Hg, screen on an individual basis according to CHD risks and benefits. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Colorectal Cancer Screening For Average Risk Adults&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen for colorectal cancer using fecal occult blood test (FOBT), sigmoidoscopy, or colonoscopy, in adults (excluding those with specific inherited syndromes - Lynch syndrome and familial adenomatous polyposis, and inflammatory bowel disease [IBD]) beginning at age 50 years and continuing until age 75 years &lt;strong&gt;[A]&lt;/strong&gt;. Screening intervals assuming 100% adherence to the regimen: Annual FOBT, sigmoidoscopy every 5 years combined with high-sensitivity FOBT every 3 years, or screening colonoscopy every 10 years. The risks and benefits of screening methods vary. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommend against routine screening for colorectal cancer in adults age 76 to 85 years &lt;strong&gt;[C]&lt;/strong&gt;. Considerations may support colorectal cancer screening in an individual patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommend against screening for colorectal cancer in adults older than age 85 years &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Osteoporosis Screening With Dual-Energy X-ray Absorptiometry (DXA) Scan&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen for osteoporosis in women aged 65 years or older &lt;strong&gt;[B]&lt;/strong&gt;. Optimal screening interval not known. Repeating DXA within eight years does not improve prediction of fractures. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screen women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men &lt;strong&gt;[I]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cervical Cancer Screening, Pap Smear&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen women age 21 to 65 years with cytology every 3 years, or, for women age 30 to 65 years who want to lengthen the screening interval, screen with a combination of cytology and human papillomavirus (HPV) testing every 5 years &lt;strong&gt;[A]&lt;/strong&gt;. Testing for HPV before age 30 not recommended &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If not high risk, have had adequate screening with normal Pap smears, recommend against screening women older than age 65 &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine Pap smear screening not recommended in women who have had a total hysterectomy for benign disease or age less than 21 &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Mammography With or Without Clinical Breast Exam (CBE)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Biennial screening mammography for women aged 50 to 74 years &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older &lt;strong&gt;[I]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommend against teaching breast self-examination (BSE) &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The current evidence is insufficient to assess the additional benefits and harms of either CBE, digital mammography, or magnetic resonance imaging (MRI), beyond screening mammography in women 40 years or older &lt;strong&gt;[I]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prostate Cancer Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommend against routine screening for prostate cancer in men &lt;strong&gt;[D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Human Immunodeficiency Virus (HIV) Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Screen all patients 15 to 65 years of age &lt;strong&gt;[A]&lt;/strong&gt;. Screen all increased risk patients (no age limit) &lt;strong&gt;[A]&lt;/strong&gt; annually.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Immunizations&lt;/strong&gt;&lt;/span&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consult the &lt;a href=&quot;http://www.cdc.gov/vaccines/pubs/ACIP-list.htm&quot; title=&quot;ACIP Web site&quot; target=&quot;_blank&quot;&gt;Advisory Committee on Immunization Practices (ACIP) Web site&lt;/a&gt; for up-to-date recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tetanus, Diphtheria, and Acellular Pertussis/Tetanus-diphtheria (Tdap/Td)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After primary series, Td every 10 years. Give Tdap once after age 12.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Varicella&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two doses for persons who lack history of immunization or convincing history of infection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Zoster&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One dose after age 60, unless contraindicated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Influenza&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Annual vaccine.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pneumococcal Vaccine&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If risk factors present before age 65. (Dosing intervals depend on risk factors.) One dose for everyone 65 and older. (If a person received a first dose prior to age 65 years, give a single revaccination at age 65, if 5 years or more have elapsed since the first dose.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hepatitis A (HepA), Hepatitis B (HepB), Meningococcal&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If risk factors present.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation Grades*&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A.&lt;/strong&gt; The United States Preventive Services Task Force (USPSTF) recommends the service. There is high certainty that the net benefit is substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B.&lt;/strong&gt; The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C.&lt;/strong&gt; The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D.&lt;/strong&gt; The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I.&lt;/strong&gt; The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*The grade definitions used for this guideline are as defined by the USPSTF.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on several sources, including: The Guide to Clinical Preventive Services 2012, Recommendations of the U.S. Preventive Services Task Force (&lt;a href=&quot;http://www.ahrq.gov/clinic/prevenix.htm&quot; title=&quot;AHRQ Web site&quot; target=&quot;_blank&quot;&gt;http://www.ahrq.gov/clinic/prevenix.htm&lt;/a&gt;) and the Advisory Committee on Immunization Practices (ACIP) 2011 Immunization Recommendations (&lt;a href=&quot;http://www.cdc.gov/&quot; title=&quot;CDC Web site&quot; target=&quot;_blank&quot;&gt;www.cdc.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for adult preventive services (ages 50 to 65+), Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Potential adverse effects of aspirin (ASA) (e.g., gastrointestinal hemorrhage)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to Web site vendor to post approved guidelines to the &lt;a href=&quot;http://www.mqic.org/&quot; title=&quot;MQIC Web site&quot;&gt;MQIC Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which guidelines have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's M.D.'s and 96% of the state's D.O.'s are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to the &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;NGC Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Adult preventive services (ages 50 - 65+). Southfield (MI): Michigan Quality Improvement Consortium; 2013 Mar. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on several sources, including: The Guide to Clinical Preventive Services 2012, Recommendations of the U.S. Preventive Services Task Force (&lt;a href=&quot;http://www.ahrq.gov/clinic/prevenix.htm&quot; title=&quot;AHRQ Web site&quot; target=&quot;_blank&quot;&gt;http://www.ahrq.gov/clinic/prevenix.htm&lt;/a&gt;) and the Advisory Committee on Immunization Practices (ACIP) 2011 Immunization Recommendations (&lt;a href=&quot;http://www.cdc.gov&quot; title=&quot;CDC Web site&quot; target=&quot;_blank&quot;&gt;www.cdc.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2005 Jul (revised 2013 Mar)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Directors' Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships as well.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Adult preventive services (50-65+). Southfield (MI): Michigan Quality Improvement Consortium; 2011 Apr. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.org/pdf/mqic_adult_preventive_services_ages_50_to_65plus_cpg.pdf&quot; title=&quot;MQIC Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on November 28, 2005. The updated information was verified by the guideline developer on December 19, 2005. This NGC summary was updated by ECRI on October 16, 2006. The updated information was verified by the guideline developer on November 3, 2006. This NGC summary was updated by ECRI Institute on November 26, 2008. The updated information was verified by the guideline developer on December 4, 2008. This NGC summary was updated by ECRI Institute on July 22, 2011. The updated information was verified by the guideline developer on September 2, 2011. This NGC summary was updated by ECRI Institute on August 22, 2013. The updated information was verified by the guideline developer on October 2, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
